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Title 
Cognitive estimation in non-demented Parkinson’s disease  
Abstract 
Background: The Cognitive Estimation Test (CET) is widely used in clinical and research settings 
to assess the ability to produce reasonable estimates to items that individuals would not know that 
the exact answer (e.g., “How fast do race horses run?”). Objective: In this study, we examined the 
performance of non-demented Parkinson’s Disease (PD) patients on the CET, since previous studies 
reported heterogeneous results about possible cognitive estimation impairments in this population. 
We also examined whether PD patients improve their performance if given the chance to reconsider 
their initial CET responses. Methods: Thirty non-demented idiopathic PD patients and thirty 
healthy controls matched in age, gender and years of education performed the two parallel forms of 
Italian CET. The estimation scores for initial and final responses as well as the number of times 
individuals changed their answers were examined. Additional neuropsychological tests, evaluating 
intellectual, frontal executive, speed of processing, naming and arithmetical abilities, were also 
administered. Results: The PD group were not significantly poorer than healthy controls at 
estimating the answers to items on either CET versions. Moreover, PD patients did not significantly 
differ in their initial and final responses or number of response changes. Performance on the CET 
was significantly related to performance on a global measure of executive function, processing 
speed and arithmetic. However, when CET performance was considered in terms of the different 
components identified in MacPherson et al. (2014), PD patients were impaired compared to controls 
on the component involving mainly, but not exclusively, length-related estimations.  Conclusions: 
Non-demented PD patients have mild impairments in cognitive estimation ability, which may 
depend on the estimations they are required to provide. 
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INTRODUCTION 
 
The Cognitive Estimation task (CET) assesses the ability to produce estimations in response 
to questions that individuals do not know the exact answer to (Shallice, & Evans, 1978). The CET 
is widely used as a test of executive dysfunction with the generation of bizarre estimates thought to 
be associated with damage to processes associated with the frontal lobes of the brain (Shallice, & 
Evans, 1978; Smith, & Milner, 1984, 1988; MacPherson, Wagner, Murphy, Bozzali, Cipolotti, & 
Shallice, 2014; D’Aniello, Scarpina, Albani, Castelnuovo, & Mauro, 2015a; D'Aniello, 
Castelnuovo, & Scarpina, 2015b).  
Despite the cognitive profile of Parkinson’s Disease (PD) being characterized as executive 
dysfunction (e.g., Gotham, Brown, & Marsden, 1988; Levy et al., 2002), few studies have examined 
the ability of individuals with Parkinson’s Disease (PD) to perform the CET. Those studies that 
have do not reach a consensus whether PD results in poorer cognitive estimation abilities compared 
to healthy controls. Most PD studies have concentrated on time estimation abilities where non-
demented medicated (Smith, Harper, Gittings, & Abernethy, 2007; Nombela, Rittman, Robbins, & 
Rowe, 2014) and non-medicated (Pastor, Artieda, Jahanshahi, & Obeso, 1992) PD individuals are 
significantly poorer than healthy controls at estimating time intervals. These time estimation 
impairments are thought to be due to frontal executive dysfunction rather than impaired temporal 
processes (Harrington, Castillo, Greenberg, Song, Lessig, Lee, & Rao, 2011). In terms of the CET, 
Bullard, Fein, Gleeson, Tischer, Mapou and Kaplan (2004) found that demented PD individuals 
produced significantly poorer estimates than controls for weight- and quantity-related estimations, 
but not time- or distance-related estimations. However, in non-demented PD individuals, 
Appollonio and colleagues (2003) did not find deficits in CET, with only 6% of the studied 
participants performing below the impaired cut-off. More recently, our own work has reported 
cognitive estimation deficits in non-demented medicated PD patients, but again in only a small 
number of individuals (approximately 16% of the studied participants were pathological – below 
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the 5th percentile; 27% of the studied participants were borderline – between the 5th and 10th 
percentile) when compared against normative data cut-offs (D’Aniello et al., 2015a). Overall, these 
findings suggest that cognitive estimation impairments in PD are mild, if reported at all.   
In the present work, we focused on investigating estimation in PD further using the more 
recent version of the CET (MacPherson et al., 2014; Scarpina, D’Aniello, Mauro, Castelnuovo, & 
MacPherson, 2015). One important feature of this CET, which exists as English- (MacPherson et 
al., 2014) and Italian-speaking (Scarpina et al., 2015) versions, is the inclusion of an additional 
administration step. This step encourages individuals to consider, and change if necessary, their 
responses before committing to a final response. The aim was to reduce responses where 
individuals simply respond with the first answer that comes to mind, without monitoring the 
appropriateness of that response.  
We focused on individuals with non-amnestic, single-domain PD to reduce the 
heterogeneity in our PD sample, and because it is the most common subtype of non-demented PD; 
the executive impairments of which are thought to predict later development of dementia (Mahieux, 
Fenelon, Flahault, Manifacier, Michelet, & Boller, 1998; Levy et al., 2002; Janvin, Aarsland, & 
Larsen, 2005). We examined the estimation scores for participants’ initial and final responses to 
examine whether PD patients improve their CET performance if given the chance to reconsider 
their responses. The number of times individuals changed their answers was also examined. 
 
MATERIALS AND METHODS 
 
Participants 
Thirty non-demented PD patients (male = 9, female = 21) aged between 33 and 83 years (M 
= 66.67; SD = 11.69) and 30 healthy control participants (male = 9; female = 21) aged between 44 
and 81 years (M = 62.93; SD = 8.84) took part in this study. The PD patients had a mean education 
of 10.97 years (SD = 4.49; range = 5-21) and the control group had a mean education of 9.40 years 
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(SD = 3.39; range = 5-17). All participants were right-handed and native Italian speakers. The PD 
patients were recruited through the Division of Neurology and Neurorehabilitation at San Giuseppe 
Hospital in Piancavallo (VCO), which specializes in the diagnosis, treatment and rehabilitation of 
neurodegenerative diseases including PD. As part of a routine yearly hospitalization for a period of 
7-18 days, PD patients are given a medical health check, a drug efficacy assessment, a 
neuropsychological assessment, and physiotherapy.  
The PD group had a mean disease duration of 8.13 years (SD = 4.81) and their unified 
Parkinson’s disease rating scale (UPDRS) (Fahn, & Elton, UPDRS Program Members, 1987) scores 
ranged between 14 and 66 out of 260 (M = 37.07, SD = 14.99). Their mean Levodopa equivalent 
dose was 550mg/day (SD = 303.18). Inclusion criteria were: a diagnosis of idiopathic PD according 
to the UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria (Hughes, Daniel, 
Kilford, & Lees, 1992); no deficit on any cognitive domain except the executive domain (non-
amnestic, single-domain PD-MCI subtype; Litvan et al., 2012); no deficits severe enough to impair 
daily life (social, occupational, or personal care), over and above motor or autonomic symptoms 
(Emre et al., 2007); a score of 24 or more out of 30 on the Mini-Mental State Examination (MMSE) 
Folstein, Folstein, & McHugh, 1975) (M = 27.70, SD = 1.94); and written informed consent to use 
their clinical data. Exclusion criteria were evidence of other neurological (e.g., ictus, traumatic brain 
injury) or pathological conditions (e.g., psychiatric syndromes, potus). The clinical details are 
reported in Table 1. 
  
 [Table 1 around here] 
 
The healthy participants were not patients of the hospital, and were recruited through 
personal contact with the researchers or word-of-mouth. No control participant had a previous 
history of head injury or stroke, major neurological or psychiatric illness, or alcohol abuse. The PD 
and healthy control groups did not significantly differ in terms of their age, t(58) = 1.39; p = 0.16, 
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or education, t(58) = 1.52; p = 0.13. The study was approved by the ethical committee of IRCSS 
Istituto Auxologico Italiano and was performed in compliance with the Declaration of Helsinki. All 
participants gave their written consent to take part in the study. 
 
Neuropsychological assessment 
Background neuropsychological measures. The background neuropsychological tests were 
administered to the PD patients as part of their inpatient stay but were also administered to the 
healthy control group who took part in the study. Clock Drawing was administered (Agrell & 
Dehlin, 1998; Esteban-Santillan, Praditsuwan, Veda, & Geldmacher, 1998; Storey, Rowland, Basic, 
& Conforti, 2001), as it is considered predictive of dementia in primary care (Kirby, Denihan, 
Bruce, Coakley, & Lawlor, 2001). Abstract reasoning was assessed using Raven’s Coloured 
Progressive Matrices (Raven, Raven, & Court, 1998), verbal intelligence through the Brief 
Intelligence Test (Isella, Villa, Forapani, Piamarta, Russo, & Appollonio, 2005), and general 
knowledge through the WAIS information subtest (Wechsler, 1997). Processing speed was 
measured using Trail Making Test Part A (Reitan, & Wolfson, 1985; Giovagnoli, Del Pesce, 
Mascheroni, Simoncelli, Laiacona, & Capitani, 1996). Naming and arithmetical abilities were 
assessed using the Oral Denomination task from Batteria per l'Analisi dei Deficit Afasici (BADA) 
(Miceli, Laudanna, Burani, & Capasso, 1994) and the Graded Difficulty Arithmetic (McKenna, & 
Warrington, 1983) respectively. 
Frontal executive abilities were assessed using the Frontal Assessment Battery (FAB) 
(Dubois, Slachevsky, Litvan, & Pillon, 2000; Appollonio et al., 2005). The Stroop Test (Stroop, 
1935; Caffarra, Vezzadini, Dieci, Zonato, & Venneri, 2002) was also administered to assess 
inhibition: in this version, three different conditions were presented: i) participants read color-words 
printed in black ink (W); ii) participants stated the color of colored circles (C); iii) participants 
stated the color of color-words printed in colored ink (CW). Two scores were derived: a time 
interference score based on execution time, and an error interference score based on number of 
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errors (Caffarra et al., 2002). Both scores were derived according to the following formula: I = CW-
[(W + C)/2]. Set shifting was measured using the Trail Making Test Part B (Reitan, & Wolfson, 
1985; Giovagnoli et al., 1996) and finally, Digit Span Backwards (Monaco, Costa, Caltagirone, & 
Carlesimo, 2013) was used to assess focused attention and manipulation within working memory 
(Baddeley, 1974, 2000).  
All neuropsychological tests were scored according to the procedures described in their 
original articles or test manuals. PD patients were considered impaired if their performance was 
below the 5th percentile and borderline if their performance was between the 5th and 10th percentile 
on the cut-offs for the standardized Italian versions of the tests. 
 
Cognitive Estimation Test. All participants performed both versions A and B of the Italian 
version (Scarpina et al., 2015) of the Cognitive Estimation Test (CET, MacPherson et al., 2014). 
The questions were asked out loud by the experimenter and participants gave their answers orally. 
Participants were instructed that there was no exact answer for most questions or it was unlikely 
they would know the answer so they should provide their best guess or estimate.  
Following the standard CET instructions (MacPherson et al., 2014; Scarpina et al., 2015), 
participants could respond using any unit of measurement and were given the opportunity to change 
their response if they decided that their first response was not a reasonable estimate; moreover, they 
could take as much as time as they needed to produce their estimates. All responses produced by 
participants were recorded. Initial and final responses for each individual CET item were scored 0, 
1, 2 or 3 points according to the normative data from 227 healthy Italian participants (Scarpina et 
al., 2015). A score of 0 was awarded for responses that were deemed normal and fell between the 
20th and 80th percentile. One point was awarded for responses considered quite extreme and were 
equal to or more than the 10th but less than the 20th percentile or more than the 80th percentile but 
less than or equal to the 90th percentile. Two points were awarded to responses considered extreme 
that were more than or equal to the 5th percentile but less than the 10th percentile or more than the 
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90th percentile but less than or equal to the 95th percentile. Finally, 3 points were awarded to very 
extreme responses that were less than the 5th or more than the 95th percentile. Where a response 
corresponded to more than one percentile category, the response was awarded the fewer number of 
points. Therefore, participants could obtain a maximum error score of 27 for each parallel CET 
version (version A and version B) where a higher score indicates poorer cognitive estimation 
abilities.  
 
Data analyses 
Firstly, independent samples t-tests were conducted to examine differences between the PD 
group and the healthy control group performing the background neuropsychological tests. In cases 
where the assumption of normality was violated, non-parametric Mann-Whitney U tests were used 
instead. Independent samples t-tests or Mann-Whitney U tests were then conducted to examine 
differences between the PD group and the healthy control group on CET-A and B. PD performance 
on the two CET versions and healthy control performance on the two CET versions were also 
compared independently using Wilcoxon tests. The p-values for these group comparisons were 
corrected for simultaneous comparisons using False Discovery Rate (FDR) where the corrected p-
values are calculated using the actual p-values produced rather than the number of comparisons 
made (Benjamini & Hochberg, 1995). 
Spearman correlations were conducted to explore the relationship between performance on 
the two CET versions and age, education, disease duration, patients’ unified Parkinson’s disease 
rating scale score (UPDRS) (Fahn et al., 1987) and their Levodopa equivalent dose (LED). 
Spearman correlations were also conducted to explore the relationship between performance on 
CET-A and B and the neuropsychological tests in the PD patients and the control group; the p-
values for these correlations were also corrected for simultaneous comparisons using FDR.  
Finally, the Wilcoxon Signed Ranks Test was used in order to assess possible differences 
between the first total CET score (i.e., based on the first answer provided by participants) and the 
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final total CET score (i.e., based on the final answer provided by participants), for the two groups 
independently for both CET versions. The overall number of changes made by the PD group and 
the healthy control group for both CET-A and B versions were compared using Mann-Whitney U 
tests. Spearman correlations were conducted to explore the relationship between the first and final 
CET-A and B measures and the neuropsychological tests in the PD patients and the control group; 
again the p-value was FDR-corrected for multiple comparisons.  
 
 
RESULTS 
 
Background neuropsychological measures. Figures 1a and 1b demonstrate the percentage of 
PD participants who were classified as impaired (<5th percentile), borderline (5th-10th percentile) 
and unimpaired (>10th percentile) on the neuropsychological tests. 
 
[Figures 1a and 1b around here] 
 
In terms of our healthy control group, only 0.6% were classified as impaired and 0.3% as 
borderline on Digit Span Backwards. On the Frontal Assessment Battery, only 0.3% of healthy 
controls were categorized as impaired and 0.3% as borderline. No other neuropsychological tests 
demonstrated impaired or borderline performance in our healthy participants. 
The means and standard deviations for performance on the neuropsychological tests are 
reported in Table 2. The results demonstrated that although the PD participants tended to perform 
more poorly than the healthy control group on the majority of the neuropsychological tests, the two 
groups did not significantly differ on any of these measures when the p-values were FDR adjusted 
for multiple comparisons.  
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[Table 2 around here] 
 
Cognitive Estimation Test. The gender adjusted scores of the PD patients and healthy 
controls on both versions of the CET are demonstrated in Table 3. The PD patients did not achieve 
significantly higher error scores (i.e., poorer performance) than the healthy controls on either CET 
version. Performance on the two versions of the CET did not significantly differ in the PD group, 
Z(30) = 200.0; p = 0.70, or in the healthy control group, Z(30) = 117.5; p = 0.03. See Figure 1a for 
the percentage of PD participants who were classified as impaired, borderline and unimpaired on 
the two versions of the CET. In the healthy control group, only 0.6% were impaired and 0.3% were 
borderline on CET-A and 0.3% were impaired on CET-B. The remaining participants were 
unimpaired on the two CET versions. 
 
[Table 3 around here] 
 
We also considered the PD patients’ and healthy controls’ scores based on the CET principal 
component (PC) factor structure identified in MacPherson et al. (2014). Considering the three 
components in version A, the PD group had significantly higher error scores on PC2 compared to 
healthy controls, t(49.43) = 2.98; p = 0.004. No significant group differences were found for PC1, 
t(58) = 1.36; p = 0.17, or PC3, t(58) = 1.07; p = 0.28 (see Table 3). Considering the four 
components in version B, the PD group had significantly higher error scores compared to the 
healthy control group for PC2, t(52.85) = 2.33; p = 0.02. However, significant differences did not 
emerge for PC1, t(58) = 1.22; p = 0.23, PC3, t(49.47) = 1.99; p = 0.05, or PC4, t(58) = 1.36; p = 
0.17. Both PC2 components of CET-A and CET-B largely included length-related estimations. 
 
 CET correlations with demographic and clinical variables. In the PD group, neither version 
of the CET significantly correlated with age, education, disease duration, UPDRS score, or LED 
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dosage. In the healthy controls, the CET versions did not significantly correlate with age or 
education. The correlational analyses are reported in Table 4. 
 
[Table 4 around here] 
 
 CET correlations with background neuropsychological scores. The correlations between 
CET performance and performance on the neuropsychological background tests are demonstrated in 
Table 5. In the PD group, performance on CET-A was significantly related to poorer performance 
on the Frontal Assessment Battery, Trail Making Test Part A, and Graded Difficulty Arithmetic, 
whereas CET-B only significantly correlated with performance on the Graded Difficulty 
Arithmetic. In the healthy control group, no significant correlations were found between 
performance on the CET and the background measures.  
 
[Table 5 around here] 
 
Initial versus final CET scores. In the PD group, Wilcoxon Signed Ranks Test showed no 
significant difference between the initial (M = 8.56; SD = 5.11) and final (M = 8.23; SD = 4.88) 
CET-A error scores for the PD group, Z(30) = -1.38; p = 0.16; a similar result emerged in relation 
to the healthy controls (initial error score: M = 6.80; SD = 3.71; final error score: M = 6.80; SD = 
3.94), Z(30) = -0.10; p = 0.91. The two groups also changed their estimation responses a similar 
number of times (PD group: M = 0.46; SD = 1.00; healthy control group: M = 0.63; SD = 0.80), 
U(60) = 372.5; p = 0.18. 
 In the PD group performing CET-B, Wilcoxon Signed Ranks Tests showed that no 
significant difference emerged between the initial (M = 7.83; SD = 4.89) and final (M = 7.86; SD = 
4.86) error scores, Z(30) = -0.27; p = 0.78; however, a significant difference emerged for the 
healthy controls (initial error  score: M = 5.56; SD = 3.56; final error score: M = 5.23; SD = 3.61), 
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Z(30) = -2.27; p = 0.02, suggesting an improvement in their estimation accuracy. No significant 
difference in the number of times the two groups changed their estimates was found (PD group: M 
= 0.46; SD = 1.00; healthy control group: M = 0.63; SD = 0.76), U(60) =360.5; p = 0.12. 
 
DISCUSSION 
 
The aim of the current study was to examine further estimation abilities in non-demented 
PD. Despite some PD individuals being impaired on the CET according to the cut-offs for the 
standardized versions, significant differences between the PD and healthy control groups were not 
found on either version of the CET (Scarpina et al., 2015). This supports previous results about 
which only small numbers of non-demented PD patients perform below the cut-off on other CET 
versions (Appollonio et al., 2003; D’Aniello et al., 2015a). In addition, our results showed that the 
PD and healthy control groups did not significantly differ in their initial and final responses 
provided or the number of response changes, which suggests that PD patients do not improve their 
CET performance if given the opportunity to revise their initial responses. When encouraged to 
consider their responses before finally committing, it was the healthy control group who corrected 
their responses on CET-B to achieve a better estimation score. From the current data, it is not clear 
why this is the case, but possible explanations might be that the CET-B items elicit faster initial, 
incorrect responses, the items are more difficult to estimate or participants are less confident about 
their responses to these items. 
We found that CET performance in our PD patients was significantly related to their global 
executive abilities as measured by their FAB total score (CET-A only), speed of processing (CET-A 
only) and arithmetical abilities (CET-A and CET-B). These findings are in line with previous 
research that suggests that the CET is a complex task that relies on several cognitive abilities in 
order to perform the task successfully (Shoqeirat, Mayes, MacDonald, Meudell, & Pickering, 1990; 
Liss, Fein, Bullard, & Robins, 2000; Brand, Kalbe, Fujiwara, Huber, & Markowitsch, 2003a; 
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Brand, Fujiwara, Kalbe, Steingass, Kessler, & Markowitsch, 2003b; Gansler, Varvaris, Swenson, & 
Schretlen; 2014; MacPherson et al., 2014; D’Aniello et al., 2015b). Our findings also suggest that 
versions A and B of the CET involve different cognitive processes in order to perform the tasks 
successfully.  
Our work suggests that CET impairments in non-demented PD are mild. When considered 
as a group, no differences were found between PD patients and healthy controls. However, there 
were a small number of PD patients who were categorized as impaired in terms of CET 
performance based on normative data cut-offs. Moreover, when CET performance was examined 
based on the factor structure identified in MacPherson et al. (2014), our PD group performed more 
significantly poorly than healthy controls on the second principal component of the CET, which 
mainly involves items estimating length. In previous studies, time estimation has been reported to 
consistently show deficits in non-demented PD, with individuals performing significantly more 
poorly than healthy controls when estimating time intervals (Pastor et al., 1992; Smith et al., 2007; 
Nombela et al., 2014). Together, these findings suggest that specific categories of estimation may 
indicate deficits in PD patients.  
PD is a heterogeneous disease with various subtypes, which is possibly due to differences in 
the mechanisms that underlie PD and complications of dopamine therapy (van Rooden et al., 2011). 
As our PD sample participants were largely similar in terms of their age and mean disease duration, 
it is difficult to determine from our current data whether different PD subtypes impact impulsivity 
differently. However, future work might explore this further in a larger PD sample. We also 
acknowledge that the MMSE is considered a less sensitive measure of cognitive status in PD 
compared to the Montreal Cognitive Assessment Battery (MOCA; Nasreddine et al., 2005), as the 
MOCA also assesses executive, visuospatial and memory abilities (Aarsland, 2016; Biundo et al., 
2016). A limitation of our study may be the inclusion of some PD individuals in the earliest stages 
of dementia, who were not detected using the MMSE.  
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In summary, the ﬁndings of our study suggest that CET impairments in non-demented PD 
patients are mild. When considered as a group, no differences in overall CET performance were 
found between PD patients and healthy controls. Moreover, non-demented PD patients do not 
improve their CET performance if given the opportunity to reassess their initial cognitive estimates. 
However, there were a small number of PD patients who were categorized as impaired based on 
existing cut-off scores from normative data and a subset of CET items demonstrated poorer 
estimation in non-demented PD patients compared to controls. These findings provide evidence for 
the multidimensional nature of the CET, with only certain estimations resulting in impaired PD 
performance. 
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TABLE 1 
Demographic and clinical details for the non-demented Parkinson’s disease participants.  
 
Age Education Sex 
Disease  
duration 
H&Y 
stage 
UPDRS 
score 
LED Medication 
76 
 
15 
 
F 
 
17 
 
4 
 
46 
 
400 
 
rotigotine;  
amantadine;apomorphine 
65 13 F 8 3 38 150 pramipexole 
68 13 M 15 3 40 350 quetiapine 
60 13 M 8 3 23 550 pramipexole; selegiline 
79 7 F 19 3 42 850 pramipexole 
68 8 F 19 3 46 575 pramipexole, rotigotine 
75 13 F 8 2 18 300 - 
75 13 M 8 4 56 700 amantadine;apomorphine 
71 3 F 3 3 44 450 - 
62 13 F 8 3 36 650 pramipexole 
74 3 F 14 4 64 1200 amantadine; quetiapine 
75 5 F 5 3 38 700 ropinirole 
47 
 
8 
 
M 
 
4 
 
1 
 
14 
 
400 
 
pramipexole; rotigotine; 
rasagiline 
37 21 M 5 1 16 200 - 
82 13 F 11 4 66 900 quetiapine 
62 13 F 5 3 35 275 pramipexole; rasagiline 
69 13 F 1 1 16 100 rotigotine 
83 18 M 8 2 28 400 - 
67 13 M 4 2 26 200 rasagiline; ropinirole 
64 8 F 1 2 20 300 - 
69 8 F 7 4 32 700 rotigotine; rasagiline 
58 5 M 13 2 26 550 pramipexole; rasagiline 
33 
 
18 
 
F 
 
8 
 
3 
 
42 
 
600 
 
rotigotine; rasagiline; 
amantidine 
78 10 F 5 3 34 400 - 
71 8 M 15 3 54 900 - 
72 15 F 9 3 50 1100 pramipexole 
55 13 F 6 4 65 300 - 
65 8 F 2 2 22 550 pramipexole 
73 5 M 10 - - - - 
67 13 F 11 3 38 1200 amatindine; ropinirole 
Mean 66.67 10.97  8.13  37.07 550.00  
SD 11.69 4.49  4.81  14.99 303.18  
Median 68.50 13.00  7.00  38.00 550.00  
H&Y stage = Hoehn & Yahr stage; UPDRS score = Unified Parkinson’s disease rating scale; LED 
= Levodopa equivalent dose; M = male; F = female. Education and Disease duration expressed in 
years. Dosage of L-dopa expressed in mg/day. 
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TABLE 2  
The means and standard deviations (in parentheses) for the scores of the PD patients and healthy 
control group performing the background neuropsychological tests.  
 
Neuropsychological test PD group Healthy group Statistic p 
Clock Drawing Test (max = 10) 7.55 (3.34) 9.35 (1.39) 316.5a 0.03 
Raven’s Coloured Progressive Matrices 
(max = 36) 
26.92 (6.74) 
 
29.97 (3.60) 
 
2.00b 
 
0.05 
 
Brief Intelligence Test (max =108) 6.53 (7.67) 6.93 (7.50) 447.5a 0.97 
WAIS - information subtest (max = 29) 18.11 (6.69) 18.17 (6.46) 0.03b 0.97 
Frontal Assessment Battery (max = 18) 14.47 (2.47) 15.77 (2.06) 304.5a 0.03 
 Similarities (max = 3) 1.87 (0.82) 2.33 (0.92) 300a 0.01  
 Lexical fluency (max = 3) 2.57 (0.68) 2.87 (0.35) 354a 0.05 
 Motor series (max = 3) 2.47 (0.94) 2.63 (0.77) 415.5a 0.51 
 Conflicting instructions (max = 3) 2.63 (0.81) 2.77 (0.50) 431.5a 0.70 
 Go-no go (max = 3) 1.93 (0.91) 2.27 (0.91) 357a 0.14 
 Prehension behaviour (max = 3) 3.00 (0.00) 2.97 (0.18) 435a 0.31 
Stroop Test – speed index 28.79 (15.32) 18.52 (13.22) 626a 0.01 
Stroop Test – error index (max = 30) 5.58 (8.71) 1.00 (1.33) 608.5a 0.02 
Digit Span Backward (max = 8) 3.60 (1.10) 4.30 (1.62) 323a 0.05 
Trail Making Test – A 64.74 (39.77) 50.00 (23.25) 491.5a 0.16 
Trail Making Test – B 111.14 (63.06) 101.17 (55.53) 369.5a 0.46 
Oral Denomination – Bada (max = 30) 25.43 (4.51) 27.33 (1.37) 348.5a 0.12 
Graded Difficulty Arithmetic (max = 24) 11.78 (6.07) 15.53 (6.08) 2.33b 0.02 
max = maximum score; a = U; b = t; p-values adjusted using FDR   
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TABLE 3 
The scores and standard deviations for the PD and healthy control groups performing both versions 
of the CET and for the CET factors derived in MacPherson et al. (2014).  
  PD 
group 
Healthy 
group 
  
  M (SD) M (SD) U p 
CET A First Error Score 8.56 (5.11) 6.80 (3.71) 538.5 0.18 
 
Final Error Score 8.23 (4.88) 6.80 (3.96) 505.0 0.41 
 Number of changes 0.46 (1.00) 0.63 (0.80) 372.5 0.18 
    t p 
 PC1 4.26 (2.85) 3.26 (2.82) 1.36 0.17 
 PC2 4.30 (2.94) 2.40 (1.89) 2.98 0.004* 
 PC3 1.70 (1.60) 2.16 (1.76) 1.07 0.28 
CET B First Error Score 7.83 (4.89) 5.56 (3.56) 568.0 0.82 
 
Final Error Score 7.86 (4.86) 5.23 (3.61) 592.5 0.03* 
 Number of changes 0.46 (1.00) 0.63 (0.76) 360.5 0.12 
    t p 
 PC1 3.33 (2.74) 2.56 (2.12) 1.20 0.23 
 PC2 2.76 (2.28) 1.56 (1.65) 2.33 0.02* 
 PC3 2.73 (2.46) 1.66 (1.58) 1.99 0.05 
 PC4 2.86 (2.5) 2.1 (1.78) 1.36 0.17 
* p < 0.05  
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TABLE 4 
Spearman correlational analyses between the parallel forms of the CET, and the demographic and 
clinical variables in the PD and healthy control groups.  
 
  
 
Age Education Disease 
Duration 
UPDRS LED 
PD CET A 0.42 -0.14 0.20 0.09 0.03 
Patients CET B 0.03 -0.13 0.14 0.07 0.12 
Healthy  CET A 0.12 0.13 - - - 
Controls CET B 0.41 -0.07 - - - 
UPDRS = Unified Parkinson’s disease rating scale; LED = Levodopa equivalent dose
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TABLE 5 
Spearman correlational analyses between the parallel forms of the CET and the background neuropsychological scores for the PD and healthy 
control groups.  
  
 
 
 
Clock 
Drawing 
Test 
Raven’s 
Coloured 
Progressive 
Matrices 
Brief 
Intelligence 
Test 
WAIS - 
information 
subtest 
Frontal 
Assessment 
Battery 
Stroop 
Test – 
speed 
index 
Stroop 
Test – 
error  
index 
Digit 
Span 
Backward 
Trail 
Making 
Test-A 
Trail 
Making 
Test-B 
Oral 
Denomination 
- Bada 
Graded 
Difficulty 
Arithmetic 
PD    
CET A -0.38 -0.30 0.05 -0.27 -0.47* 0.00 0.41 -0.29 0.51* 0.38 -0.37 -0.48* 
CET B -0.27 -0.36 0.16 -0.41 -0.27 -0.15 0.06 -0.35 0.31 0.07 -0.15 -0.58* 
Controls    
CET A 0.02 -0.26 0.16 -0.28 -0.06 0.02 0.44 -0.24 0.00 0.02 -0.01 -0.37 
CET B -0.15 -0.26 -0.01 -0.16 -0.11 0.18 0.27 -0.34 0.28 0.24 -0.24 -0.46 
* p ≤ 0.01 
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FIGURE CAPTION 
 
Figures 1a and 1b. Percentage of PD participants’ who were impaired, borderline and 
unimpaired on the neuropsychological background tests and CET-A and B according to 
Italian normative data. 
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